Evidence map›Paper›PMID 37796807›Full record

ArticlePloS one2023

Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.

Udit Nindra, Abhijit Pal, Vivienne Lea, Stephanie Hui-Su Lim, Kate Wilkinson, Ray Asghari, Tara L Roberts, Therese M Becker, Mahtab Farzin, Tristan Rutland and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Udit NindraDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.ORCID 0000-0002-2612-9502
Abhijit PalDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Vivienne LeaDepartment of Anatomical Pathology, Liverpool Hospital, Liverpool, Sydney, Australia.
Stephanie Hui-Su LimDepartment of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, New South Wales, Australia.ORCID 0000-0001-5940-7137
Kate WilkinsonDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Ray AsghariDepartment of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
Tara L RobertsIngham Institute for Applied Medical Research, Liverpool, Australia.
Therese M BeckerIngham Institute for Applied Medical Research, Liverpool, Australia.
Mahtab FarzinDepartment of Anatomical Pathology, Liverpool Hospital, Liverpool, Sydney, Australia.
Tristan RutlandSchool of Medicine, Western Sydney University, Sydney, Australia.
Mark LeeSouth Western Clinical School, University of New South Wales, Sydney, Australia.
Scott MacKenzieSchool of Medicine, Western Sydney University, Sydney, Australia.
Weng NgDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Bin WangDepartment of Anatomical Pathology, Liverpool Hospital, Liverpool, Sydney, Australia.
C Soon LeeDepartment of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
Wei ChuaDepartment of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Liverpool Hospital · AUBankstown Lidcombe Hospital · AUUNSW Sydney · AUCamden and Campbelltown Hospitals · AUWestern Sydney University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNext generation sequencing (NGS) is increasingly used in standard clinical practice to identify patients with potentially actionable mutations. Stratification of NGS mutation tiers is currently based on the European Society of Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT[E]) Tier I-V & X. Allele frequency is also increasingly recognised as an important prognostic tool in advanced cancer. The aim of this study was to determine the genomic mutations in metastatic colorectal cancer (CRC) in an Australian multicultural population and their influence on survival outcomes.

methodsNext generation sequencing with the 50-gene panel Oncomine Precision Assay™ was used on 180 CRC tissue samples obtained across six Sydney hospitals between June 2021 and March 2022.

resultsFrom 180 samples, 147 (82%) had at least one gene mutation identified with 68 (38%) having two or more concurrent mutations. Tier I variants included RAS wild-type [EI] in 73 (41%) and BRAF V600E [EIA] in 27 (15%). Non-tier I variants include 2 (1%) ERBB2 amplification [EIIB], 26 (15%) PIK3CA hotspot mutations [EIIIA] and 9 (5%) MET focal amplifications [EIIIA]. NGS testing revealed an additional 22% of cases with Tier II & III mutations. 43% of patients also presented with potentially actionable Tier III & IV mutations. Patients with concurrent TP53 and RAS mutations had significantly reduced overall survival (6.1 months versus 21.1 months, p <0.01). High KRAS allele frequency, as defined by those with over 20% variant allele frequency (VAF), also demonstrated reduced overall survival (12.1 months versus 42.9 months, p = 0.04).

conclusionsIn addition to identifying patients with genomic alterations suitable for clinically proven standard of care therapeutic options, the 50 gene NGS panel has significant potential in identifying potentially actionable non-tier 1 mutations and therefore may become future standard clinical practice.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAustraliaHigh-Throughput Nucleotide SequencingHumansMutation

Identifiers

PMID37796807
PMCPMC10553362
OpenAlexW4387378889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.